28.12.2023 - WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) - Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief ...